Candel Therapeutics, Inc.
CADLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Candel Therapeutics, Inc. focuses on Biotechnology services and products. Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. With a market capitalization of $964.1M, it sits in small-cap territory. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Market Cap
$964.1M
Beta
-0.47
P/E (TTM)
—
P/E (Fwd)
-20.16
EPS (TTM)
$-1.47
EPS (Fwd)
$-0.63
ROE
-81.8%
ROA
-28.6%
Cash
$201.6M
Total Debt
$49.5M
Free CF
-$35.8M
52W Change
163.5%
Annual Financials
Cash vs Debt
Where CADL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CADL finished 66.88% above its 150-day moving average ($7.91) and 80.57% above its 200-day moving average ($7.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CADL overbought or oversold?
At the September 3, 2026 close, CADL's RSI(14) was 59.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $201.6M in cash comfortably exceeding the $49.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$35.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -81.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $125K (2022) to $0 (2025), a 100% decline worth watching.
CADL's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Candel Therapeutics, Inc.'s trajectory.